IP Library Granted Patent US 11,957,753
Granted Patent B2
US 11,957,753 · App. 15/966,367 · Granted Apr 16, 2024

Pharmaceutical formulations containing corticosteroids for topical administration

Inventors: Arturo Angel (Santa Rosa, CA); Gordon Dow (Greenbrae, CA)
Assignee: BAUSCH HEALTH IRELAND LIMITED
A61K47/14A61K9/0014A61K9/06A61K9/107A61K9/127A61K31/573A61K31/58A61P17/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,957,753
App. No.
15/966,367
Granted
Apr 16, 2024
Kind
B2
Abstract

Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.

Claims (33)

1. A pharmaceutical composition for topical application to the skin of an individual comprising:

a liquid oil component comprising a dicarboxylic acid ester or a monocarboxylic acid ester, and a mineral oil or a light mineral oil;

a corticosteroid at a concentration of 0.03% or less, wherein the corticosteroid is selected from the group consisting of halobetasol propionate, clobetasol, betamethasone dipropionate, diflorasone diacetate, desoximetasone, mometasone furoate, betamethasone valerate, halcinonide, fluocinonide, and amcinonide, and wherein at least 25% of the corticosteroid is solubilized in the liquid oil component at a temperature of 22° C.±2° C.; and

an aqueous component comprising water;

wherein the pharmaceutical composition does not include white petrolatum; and

wherein the pharmaceutical composition is formulated as a lotion or a cream.

2. The pharmaceutical composition of claim 1 , wherein the corticosteroid is halobetasol propionate.

3. The pharmaceutical composition of claim 1 , wherein the corticosteroid is clobetasol propionate.

4. The pharmaceutical composition of claim 1 , wherein the corticosteroid is betamethasone dipropionate.

5. The pharmaceutical composition of claim 1 , wherein the corticosteroid is diflorasone diacetate.

6. The pharmaceutical composition of claim 1 , wherein the corticosteroid is desoximetasone.

7. The pharmaceutical composition of claim 1 , wherein the concentration of the corticosteroid is about 0.01%.

8. The pharmaceutical composition of claim 1 , wherein the liquid oil component comprises a dicarboxylic acid ester, and the dicarboxylic acid ester is diethyl sebacate, diisopropyl adipate, or dibutyl sebacate.

9. The pharmaceutical composition of claim 8 , wherein the dicarboxylic acid ester is diethyl sebacate.

10. The pharmaceutical composition of claim 1 , wherein the liquid oil component comprises a monocarboxylic acid ester.

11. The pharmaceutical composition of claim 10 , wherein the monocarboxylic acid ester is isopropyl myristate.

12. The pharmaceutical composition of claim 1 , wherein the liquid oil component comprises light mineral oil.

13. The pharmaceutical composition of claim 1 , wherein the concentration of the liquid oil component is sufficient to dissolve the amount of corticosteroid in the composition at a temperature of 22° C.±2° C.

14. The pharmaceutical composition of claim 1 , wherein the liquid oil component further comprises an emulsifying agent.

15. The pharmaceutical composition of claim 1 , wherein the aqueous component further comprises one or more humectants, preservatives, chelating agents, emulsifying agents, and/or thickening agents.

16. The pharmaceutical composition of claim 1 , further comprising a pH adjusting agent.

17. The pharmaceutical composition of claim 1 , wherein the composition is formulated as an oil-in-water emulsion, a water-in-oil emulsion, or an oil-in-water-in-oil emulsion.

18. The pharmaceutical composition of claim 1 , wherein the composition is formulated as a lotion.

19. A pharmaceutical composition for topical application to the skin of an individual comprising:

a liquid oil component comprising a dicarboxylic acid ester or a monocarboxylic acid ester, and a mineral oil or a light mineral oil;

a corticosteroid at a concentration of 0.01% or less, wherein the corticosteroid is selected from the group consisting of halobetasol propionate, clobetasol, betamethasone dipropionate, diflorasone diacetate, desoximetasone, mometasone furoate, betamethasone valerate, halcinonide, fluocinonide, or amcinonide, and wherein at least 25% of the corticosteroid is solubilized in the liquid oil component at a temperature of 22° C.±2° C.; and

an aqueous component comprising water;

wherein the pharmaceutical composition does not include white petrolatum; and

wherein the pharmaceutical composition is formulated as a lotion or a cream.

20. The pharmaceutical composition of claim 19 , wherein the corticosteroid is halobetasol propionate.

21. The pharmaceutical composition of claim 1 , wherein the concentration of the corticosteroid is from about 0.01% to about 0.03%.

22. The pharmaceutical composition of claim 2 , wherein the concentration of the halobetasol propionate is about 0.01%, and wherein the dicarboxylic acid ester is diethyl sebacate.

23. The pharmaceutical composition of claim 20 , wherein the concentration of the halobetasol propionate is about 0.01%, and wherein the pharmaceutical composition is formulated as a lotion.

Assignments (17)
U.S. PATENT SECURITY AGREEMENT Recorded Nov 25, 2025
From: BAUSCH HEALTH IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 073715/0375 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061882/0708 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Nov 4, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 062078/0276 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2019
From: DOW PHARMACEUTICALS SCIENCES, INC.
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 049591/0962 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Aug 10, 2018
From: BAUSCH & LOMB INCORPORATED; DOW PHARMACEUTICAL SCIENCES, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, LTD; SOLTA MEDICAL, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A.R.L.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 046616/0261 →
SECURITY INTEREST Recorded Aug 10, 2018
From: BAUSCH & LOMB INCORPORATED; DOW PHARMACEUTICAL SCIENCES, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, LTD; SOLTA MEDICAL, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A.R.L.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 046616/0301 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2018
From: ANGEL, ARTURO; DOW, GORDON
To: DOW PHARMACEUTICAL SCIENCES, INC.
Reel/Frame 045887/0620 →